[1] WHO (2017) Global Hepatitis Report, 2017. World Health Organization, Geneva.
[2] Kim, C.W. and Chang, K.M. (2013) Hepatitis C Virus: Virology and Life Cycle. Clinical and Molecular Hepatology, 19, 17-25.
https://doi.org/10.3350/cmh.2013.19.1.17
[3] Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Heinzen, E.L., et al. (2009) Genetic Variation in IL28B Predicts Hepatitis C Treatment-Induced Viral Clearance. Nature, 461, 399-401.
https://doi.org/10.1038/nature08309
[4] Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., et al. (2009) Genome-Wide Association of IL28B with Response to Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C. Nature Genetics, 41, 1105-1109.
https://doi.org/10.1038/ng.449
[5] Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Bochud, M., et al. (2010) Genetic Variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 138, 1338-1345.
https://doi.org/10.1053/j.gastro.2009.12.056
[6] Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., Bassendine, M., et al. (2009) IL28B Is Associated with Response to Chronic Hepatitis C Interferon-Alpha And Ribavirin Therapy. Nature Genetics, 41, 1100-1104.
https://doi.org/10.1038/ng.447
[7] Ridruejo, E., Solano, A., Marciano, S., Galdame, O., Adrover, R., Cocozzella, D., Delettieres, D., et al. (2011) Genetic Variation in Interleukin-28B Predicts SVR in Hepatitis C Genotype 1 Argentine Patients Treated with PEG IFN and Ribavirin. Ann Hepatol, 10, 452-457.
[8] Thomas, D.L., Thio, C.L., Martin, M.P., Qi, Y., Ge, D., O’Huigin, C., Kidd, J., et al. (2009) Genetic Variation in IL28B and Spontaneous Clearance of Hepatitis C Virus. Nature, 461, 798-801.
https://doi.org/10.1038/nature08463
[9] Tillmann, H.L., Thompson, A.J., Patel, K., Wiese, M., Tenckhoff, H., Nischalke, H.D., Lokhnygina, Y., et al. (2010) A Polymorphism near IL28B Is Associated with Spontaneous Clearance of Acute Hepatitis C Virus and Jaundice. Gastroenterology, 139, 1586-1592.
https://doi.org/10.1053/j.gastro.2010.07.005
[10] Montes-Cano, M.A., García-Lozano, J.R., Abad-Molina, C., Romero-Gómez, M., Barroso, N., Aguilar-Reina, J., Núñez-Roldán, A., et al. (2010) Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes. Hepatology, 52, 33-37.
https://doi.org/10.1002/hep.23624
[11] Sato, M., Kondo, M., Tateishi, R., Fujiwara, N., Kato, N., Yoshida, H., Taguri, M., et al. (2014) Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis. PLoS ONE, 9, e91822.
https://doi.org/10.1371/journal.pone.0091822
[12] Balagopal, A., Thomas, D.L. and Thio, C.L. (2010) IL28B and the Control of Hepatitis C Virus Infection. Gastroenterology, 139, 1865-1876.
https://doi.org/10.1053/j.gastro.2010.10.004
[13] Kotenko, S.V., Gallagher, G., Baurin, V.V., Lewis-Antes, A., Shen, M., Shah, N.K., Langer, J.A., et al. (2003) IFN-Lambdas Mediate Antiviral Protection through a Distinct Class II Cytokine Receptor Complex. Nature Immunology, 4, 69-77.
https://doi.org/10.1038/ni875
[14] Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T.E., Kuestner, R., et al. (2003) IL-28, IL-29 and Their Class II Cytokine Receptor IL-28R. Nature Immunology, 4, 63-68.
https://doi.org/10.1038/ni873
[15] Robek, M.D., Boyd, B.S. and Chisari, F.V. (2005) Lambda Interferon Inhibits Hepatitis B and C Virus Replication. Journal of Virology, 79, 3851-3854.
https://doi.org/10.1128/JVI.79.6.3851-3854.2005
[16] Abe, H., Ochi, H., Maekawa, T., Hayes, C.N., Tsuge, M., Miki, D., Mitsui, F., et al. (2010) Common Variation of IL28 Affects Gamma-GTP Levels and Inflammation of the Liver in Chronically Infected Hepatitis C Virus Patients. Journal of Hepatology, 53, 439-443.
https://doi.org/10.1016/j.jhep.2010.03.022
[17] Bochud, P.Y., Bibert, S., Kutalik, Z., Patin, E., Guergnon, J., Nalpas, B., Goossens, N., et al. (2012) IL28B Alleles Associated with Poor Hepatitis C Virus (HCV) Clearance Protect against Inflammation and Fibrosis in Patients Infected with Non-1 HCV Genotypes. Hepatology, 55, 384-394.
https://doi.org/10.1002/hep.24678
[18] Noureddin, M., Wright, E.C., Alter, H., Clark, S., Thomas, E., Chen, R., Zhao, X., et al. (2013) Association of IL28B Genotype with Fibrosis Progression and Clinical Outcomes in Patients with Chronic Hepatitis C: A Longitudinal Analysis. Hepatology, 58, 1548-1557.
https://doi.org/10.1002/hep.26506
[19] Fabris, C., Falleti, E., Cussigh, A., Bitetto, D., Fontanini, E., Bignulin, S., Cmet, S., et al. (2011) IL-28B rs12979860 C/T Allele Distribution in Patients with Liver Cirrhosis: Role in the Course of Chronic Viral Hepatitis and the Development of HCC. Journal of Hepatology, 54, 716-722.
https://doi.org/10.1016/j.jhep.2010.07.019
[20] Di Marco, V., Bronte, F., Calvaruso, V., Capra, M., Borsellino, Z., Maggio, A., Renda, M.C., et al. (2012) IL28B Polymorphisms Influence Stage of Fibrosis and Spontaneous or Interferon-Induced Viral Clearance in Thalassemia Patients with Hepatitis C Virus Infection. Haematologica, 97, 679-686.
https://doi.org/10.3324/haematol.2011.050351
[21] Falleti, E., Bitetto, D., Fabris, C., Cussigh, A., Fornasiere, E., Cmet, S., Fumolo, E., et al. (2011) Role of Interleukin 28B rs12979860 C/T Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship with Gender and Viral Genotype. Journal of Clinical Immunology, 31, 891-899.
https://doi.org/10.1007/s10875-011-9547-1
[22] Marabita, F., Aghemo, A., De Nicola, S., Rumi, M.G., Cheroni, C., Scavelli, R., Crimi, M., et al. (2011) Genetic Variation in the Interleukin-28B Gene Is Not Associated with Fibrosis Progression in Patients with Chronic Hepatitis C and Known Date of Infection. Hepatology, 54, 1127-1134.
https://doi.org/10.1002/hep.24503
[23] Bedossa, P. and Poynard, T. (1996) An Algorithm for the Grading of Activity in Chronic Hepatitis C. Hepatology, 24, 289-293.
https://doi.org/10.1002/hep.510240201
[24] Fischer, J., Böhm, S., Scholz, M., Müller, T., Witt, H., George, J., Sarrazin, C., et al. (2012) Combined Effects of Different Interleukin-28B Gene Variants on the Outcome of Dual Combination Therapy in Chronic Hepatitis C Virus Type 1 Infection. Hepatology, 55, 1700-1710.
https://doi.org/10.1002/hep.25582
[25] Park, S.H. and Rehermann, B. (2014) Immune Responses to HCV and Other Hepatitis Viruses. Immunity, 40, 13-24.
https://doi.org/10.1016/j.immuni.2013.12.010
[26] Ank, N., Iversen, M.B., Bartholdy, C., Staeheli, P., Hartmann, R., Jensen, U.B., Dagnaes-Hansen, F., et al. (2008) An Important Role for Type III Interferon (IFN-Lambda/IL-28) in TLR-Induced Antiviral Activity. The Journal of Immunology, 180, 2474-2485.
https://doi.org/10.4049/jimmunol.180.4.2474
[27] Shindo, H., Maekawa, S., Komase, K., Miura, M., Kadokura, M., Sueki, R., Komatsu, N., et al. (2013) IL-28B (IFN-λ3) and IFN-α Synergistically Inhibit HCV Replication. Journal of Viral Hepatitis, 20, 281-289.
https://doi.org/10.1111/j.1365-2893.2012.01649.x
[28] Lalle, E., Bordi, L., Caglioti, C., Garbuglia, A.R., Castilletti, C., Taibi, C., Cristofari, F., et al. (2014) IFN-Alpha Receptor-1 Upregulation in PBMC from HCV Naïve Patients Carrying cc Genotype. Possible Role of IFN-Lambda. PLoS ONE, 9, e93434.
https://doi.org/10.1371/journal.pone.0093434
[29] Eslam, M., McLeod, D., Kelaeng, K.S., Mangia, A., Berg, T., Thabet, K., Irving, W.L., et al. (2017) IFN-λ3, Not IFN-λ4, Likely Mediated IFNL3-IFNL4 Haplotype-Dependent Hepatic Inflammation and Fibrosis. Nature Genetics, 49, 795-800.
https://doi.org/10.1038/ng.3836